ESTRO 2024 - Abstract Book

S2033

Clinical - Paediatric

ESTRO 2024

References:

1- Ducassou A., et al. Pediatric Localized Intracranial Ependymomas: A Multicenter Analysis of the Société Française de lutte contre les Cancers de l'Enfant (SFCE) from 2000 to 2013. Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):166-173. doi: 10.1016/j.ijrobp.2018.05.036. Epub 2018 May 24

2-Tensaouti F., et al. Patterns of failure after radiotherapy for pediatric patients with intracranial ependymoma. Radiother Oncol. 2017 Mar;122(3):362-367. doi: 10.1016/j.radonc.2016.12.025. Epub 2017 Jan 12.

3- Nioche C., et al. LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Charac-terization of Tumor Heterogeneity. Cancer Res 2018;78:4786–9. https://doi.org/10.1158/0008-5472.CAN-18-0125

4- https://wiki.cancerimagingarchive.net/display/Public/VASARI+Research+Project

960

Poster Discussion

Radiotherapy of pediatric standard-risk medulloblastoma: a systematic review and meta-analysis

Anneli Edvardsson 1,2 , Birgitta Lannering 3 , Jenny Gorgisyan 1,2 , Per Munck af Rosenschöld 1,2 , Thomas Björk Eriksson 4,5 1 Radiation Physics, Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden. 2 Medical Radiation Physics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. 3 Institution of Clinical Sciences, Department of Pediatrics, University of Gothenburg, Gothenburg, Sweden. 4 Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden. 5 Regional Cancer Centre West, Western Sweden Healthcare Region, Gothenburg, Sweden

Purpose/Objective:

Craniospinal irradiation (CSI) plays a crucial role in the management of pediatric medulloblastoma. In the last decades, efforts have been made to enhance the efficacy of the treatment in combination with chemotherapy. Simultaneously, several changes to the treatment protocols have been made in order to mitigate long-term toxicity, involving strategies such as lowering the prescribed dose, reducing the boost volume, implementing hyperfractionation and more conform radiotherapy techniques such as proton therapy. A systematic review and meta-analysis were performed to assess the impact of these treatment advancements on the survival of pediatric standard-risk medulloblastoma patients.

Material/Methods:

A systematic review and meta-analysis were performed using The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) methodology [1]. Peer reviewed articles written in English on studies including ≥ 10 pediatric standard-risk medulloblastoma patients aged 3-21 years treated with CSI were included. The selection was performed by three reviewers independently. Information on use of chemotherapy, fractionation, boost volume, treatment modality, CSI dose, boost dose, molecular subgroup together with the 5 year event-free survival (EFS), progression-free survival (PFS), recurrence-free survival (RFS), disease-free survival